Pharming Group N.V annual return on equity
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Return on Equity (ROE) Growth & History (PHAR)
Pharming Group N.V's return on equity was 1.02% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 1.02% | +6.40 pp |
| 2024 | 2024-12-31 | −5.38% | −0.40 pp |
| 2023 | 2023-12-31 | −4.98% | −11.86 pp |
| 2022 | 2022-12-31 | 6.88% | −1.62 pp |
| 2021 | 2021-12-31 | 8.50% | −16.59 pp |
| 2020 | 2020-12-31 | 25.10% | −19.60 pp |
| 2019 | 2019-12-31 | 44.69% | — |
Pharming Group N.V quarterly return on equity
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.61% | −1.43 pp |
| Q1 2026 | 2026-03-31 | −1.91% | — |
| Q4 2025 | 2025-12-31 | 1.96% | — |
| Q3 2025 | 2025-09-30 | 2.99% | — |
| Q2 2025 | 2025-06-30 | 2.04% | — |
Pharming Group N.V return on equity trends
Over the last five fiscal years, Pharming Group N.V's return on equity decreased from 25.10% to 1.02%, a change of −24.08 percentage points. The latest reported quarter, Q2 2026, shows 0.61%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...